



## Correction to: Adverse Effects of Physostigmine

Ann M. Arens<sup>1,2</sup> · Tom Kearney<sup>3,4</sup>

Published online: 14 August 2019  
© American College of Medical Toxicology 2019

### Correction to: *J. Med. Toxicol.*

<https://doi.org/10.1007/s13181-019-00697-z>

In “Adverse Effects of Physostigmine” by Arens et al in the July 2019 issue of JMT, reference #27 contains an error. The correct reference is as follows:

27. Rasimas JJ, Sachdeva KK, Donovan JW. Revival of an antidote: bedside experience with physostigmine. *Toxicology Communications*. 2018;2(1):85-101. <https://doi.org/10.1080/24734306.2018.1535538>

The authors and the journal respectfully apologize for this error.

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

---

The online version of the original article can be found at <https://doi.org/10.1007/s13181-019-00697-z>

---

✉ Ann M. Arens  
[Ann.Arens@hcmcd.org](mailto:Ann.Arens@hcmcd.org)

<sup>1</sup> Minnesota Poison Control System, Minneapolis, MN, USA

<sup>2</sup> Hennepin Healthcare, Department of Emergency Medicine, Hennepin County Medical Center, 701 Park Avenue, MC-R2, Minneapolis, MN 55415, USA

<sup>3</sup> California Poison Control System, San Francisco Division, San Francisco, CA, USA

<sup>4</sup> San Francisco School of Pharmacy, University of California, San Francisco, CA, USA